Physician profile
Lauren Gee
NPI 1750869640
$1,778.08
in general payments reported to CMS, 2019-2025
13 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.61 · 2020: $122 · 2021: $158 · 2022: $188 · 2023: $730 · 2024: $281 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027 · Travel and Lodging: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.73 |
| Travel and Lodging | $246.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $757.65 | 2019-2024 | Dailies Aqua Comfort Plus, Air Optix, Dailies Total1 Multifocal |
| Sun Pharmaceutical Industries INC. | $262.59 | 2020-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $255.85 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $102.77 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.44 | 2020-2021 | |
| Dompe US, INC. | $77.57 | 2024-2025 | Oxervate |
| Abbvie INC. | $74.08 | 2023-2025 | |
| Coopervision INC. | $65.15 | 2020-2023 | Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $37.33 | 2024 | Xdemvy |
| Harrow Eye, LLC | $19.80 | 2024 | Vevye |
| Tearlab Corp | $19.30 | 2024 | Scoutpro Osmolarity System |
| Oyster Point Pharma, INC. | $14.10 | 2022 | |
| Kala Pharmaceuticals, INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Gee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.